Gianni Faedda
Psychiatry · New York, NYNPI 1477609931
Payments from drug & device makers
Across 69 payments — averaging $3241.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$99K
- Teva Pharmaceuticals USA, Inc.$59K
- AbbVie$41K
- Acadia Pharmaceuticals Inc$9K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
- Sunovion Pharmaceuticals Inc.$5K
- plus $6K from 5 others
Across 1 payment — averaging $3450.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avanir Pharmaceuticals, Inc.$3K
What the payments were for
- Consulting fees$3,67568%
- Speaking & faculty fees$82815%
- Food & beverage$93917%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 29 | $98,902 |
| Teva Pharmaceuticals USA, Inc. | 7 | $59,271 |
| AbbVie | 16 | $40,676 |
| Acadia Pharmaceuticals Inc | 2 | $8,517 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $5,100 |
| Sunovion Pharmaceuticals Inc. | 4 | $5,075 |
| Alkermes, Inc. | 5 | $2,952 |
| Shire North American Group Inc | 1 | $2,500 |
| Avanir Pharmaceuticals, Inc. | 1 | $425 |
| Otsuka America Pharmaceutical, Inc. | 2 | $250 |
| Lundbeck LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,458
- LATUDA$828
- ARISTADA INITIO$365
- REXULTI$250
- INGREZZA$102
How this compares
$223,692 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClozarilClozapine | 68 | $10,037 |
| RitalinMethylphenidate Hcl | 12 | $2,425 |
| Ziprasidone Hcl | 14 | $231 |
| Lithium Carbonate ErLithium Carbonate | 17 | $211 |
| Risperidone | 14 | $101 |
| Lorazepam | 15 | $98 |
| Zolpidem Tartrate | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New York
- Michael LiebowitzNew York$7.1M
- Paul EderNew York$2.7M
- Lenard AdlerNew York$1.8M
- Ram ShrivastavaNew York$1.8M
- Jonathan KaneNew York$1.8M
- Eric HollanderNew York$1.4M
- William HapworthNew York$1.3M
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Anthony ZoghbiNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.